Despite screening programs for early detection and the approval of human papillomavirus
vaccines, around 6% of women with cervical cancer (CC) are discovered with primary …

Introduction Cervical cancer is the overall fourth most common malignancy and the fourth
most common cause of cancer-related deaths worldwide. Despite vaccination and screening …

Background Cervical cancer is the fourth most common cancer affecting women worldwide.
Despite advances in screening and human papillomavirus (HPV) vaccination, a significant …

Abstract The WHO (World Health Organization) conducted an elimination of cervical cancer
program using triple pillar intervention strategy to target 90%-70%-90% of women before the …

While screening programs and HPV vaccination have decreased the incidence of cervical
cancer, still over 13,000 cases occur in the USA annually. Early-stage cervical cancer has …

Background The GOG240 trial established bevacizumab with chemotherapy as standard
first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10 …

Cervical cancer continues to be a common cancer in women worldwide, especially in less
developed regions where advanced stage presentations are common. Addition of …

Background Patients with metastatic, recurrent, or persistent cervical cancer not amenable to
local control and/or distant metastases have a very poor prognosis, only being candidates …

Despite the available prevention and early detection strategies, advanced squamous-cell
carcinoma of the uterine cervix remains a major concern for public health. Systemic …

The management of recurrent cervical cancer depends mainly on previous treatment and on
the site and extent of recurrence. Concurrent cisplatin-based chemo-radiation is the …